Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.
Iosune BaraibarJavier RosNuria MuletFrancesc SalvàGuillem ArgilésGiulia MartiniJosé Luis CuadraEmilia SardoDavide CiardielloJosep TaberneroElena ÉlezPublished in: Expert review of molecular diagnostics (2020)
Use of targeted therapies based on biomarker testing in CRC has enabled impressive improvements in clinical outcomes in refractory patients. BRAF, MSI, NRAS and KRAS should be tested upfront in all patients given their indisputable therapeutic implications. Other molecular alterations such as HER2 and NTRK are emerging. Testing for these alterations may further improve outcomes for refractory CRC patients. Nonetheless, many key aspects remain to be defined including the optimal timing and technique for testing, the most adequate panel, and whether all patients should be tested for all alterations.